Axogen Inc vs Chart Industries Inc — how do they compare? Axogen Inc trades at $38.5 (market cap $2.06B), while Chart Industries Inc trades at $209.88 (market cap $10.05B). The key difference: Chart Industries Inc is far larger — about 4.9× Axogen Inc's market cap, and Chart Industries Inc is trading nearer its 52-week high, Axogen Inc nearer its low. Which is the better fit depends on your goals.
| AXGN | GTLS | |
|---|---|---|
Market Cap | $2.06B | $10.05B |
Sector | Technology | Technology |
52-Week High | $46.19 | $209.91 |
52-Week Low | $11.28 | $164.90 |
Enterprise Value | $1.98B | $13.57B |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
GTLS trades at $209.79, showing minimal daily movement with a -0.04% decline. The stock maintains a bullish technical signal despite recent earnings misses, with Q2 2026 results pending. Valuation metrics show elevated P/E at 629.67 but reasonable P/S at 2.33. The company faces profitability challenges with negative net income margin and ROE, though operating cash flow remains positive at $293M. Recent news highlights Baker Hughes' $13.6 billion acquisition progressing through regulatory approval.
The outlook remains cautiously optimistic given strong analyst support (54% buy rating) and the pending acquisition catalyst. However, consecutive earnings misses and negative profitability metrics present near-term risks. The technical setup suggests potential support at current levels, but fundamental improvement is needed to justify the premium valuation multiple.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Chart Industries is a leading manufacturer of highly engineered cryogenic equipment. Its products are used throughout the liquid gas supply chain, including clean energy applications like hydrogen and LNG.
Read more on GTLS →